


LOOKING TODAY AT TOMORROW'S IMMUNOTHERAPY

EXPANDING INNOVATION AND IMPACT

March 14, 2026 / Lisbon, Portugal



PROGRAM TIMES & SPEAKERS

subject to change

9:00 **WELCOME BY Manuel Abecasis (APCL)**
Presentation of APCL's program "A seu lado"

New T cell therapies: advancing innovation and optimizing impact
CHAIR: Maria Gomes da Silva (IPO Lisbon), Joaquim Sampaio Cabral (Instituto Superior Técnico, Lisbon)

9:15 Advancing CAR-based adoptive T cell immunotherapies for acute leukemia
5' Q&A **Pablo Menendez** (Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu)

9:45 Double-target CAR T cells
5' Q&A **Mariana Silva** (VOR Bio, Boston)

10:15 **COFFEE BREAK**

The promise of T cell therapies in the field of allogeneic transplantation
CHAIR: Manuel Abecasis (APCL), Carlos Pinho Vaz (IPO Porto)

10:45 Virus-specific T cells: expanding therapeutic strategies
5' Q&A **Eduardo Espada** (ULS Santa Maria)

11:15 The role of regulatory T cells in the field of allogeneic stem cell transplantation
5' Q&A **João Forjaz de Lacerda** (ULS Santa Maria, GIMM)

CAR T cells in multiple myeloma
CHAIR: Fernando Leal da Costa (IPO Lisbon), Fernanda Trigo (ULS São João)

11:45 New targets and challenges in multiple myeloma CAR T cell therapy
5' Q&A **Luis Rodriguez-Lobato** (Hospital Clínic of Barcelona)

12:15 **LUNCH**

Real-life experience with CAR T cells in the Portuguese centres
CHAIR: Maria Gomes da Silva (IPO Lisbon), José Mário Mariz (IPO Porto)

13:45 IPO Porto, **Delfim Duarte** / IPO Lisbon, **Rita Gavanha** / ULS Santa Maria, to be announced / ULS Coimbra, **Marília Gomes** / ULS São João, **Filipa Moita** / IPO Lisbon (Pediatrics), **Joaquín Duarte**

15:30 **COFFEE BREAK**

How to increase accessibility to CAR T cells treatment
CHAIR: Catarina Geraldès (ULS Coimbra), João Forjaz de Lacerda (ULS Sta. Maria)

16:00 The SHARP initiative: a think tank proposal
5' Q&A **Laura Moura e Henrique Lopes** (Nova Center for Global Health, NOVA IMS)

16:30 Lessons to be learned from a visit to a CAR T cell program
5' Q&A **Gilda Teixeira** (IPO Lisbon)

17:00 Expanding access to CAR T cell therapies through local manufacturing
5' Q&A **Susana Roncon** (IPO Porto)

17:30 **CLOSING / Manuel Abecasis (APCL), Tomás Lamas (Batazu Family)**